{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T08:28:19Z","timestamp":1794558499083,"version":"4.9.1"},"reference-count":164,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,6,14]],"date-time":"2023-06-14T00:00:00Z","timestamp":1686700800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004423","name":"World Health Organization","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004423","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.vaccine.2023.06.020","type":"journal-article","created":{"date-parts":[[2023,10,6]],"date-time":"2023-10-06T15:32:31Z","timestamp":1696606351000},"page":"S53-S75","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":42,"special_numbering":"S2","title":["Vaccine value profile for cytomegalovirus"],"prefix":"10.1016","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4785-2767","authenticated-orcid":false,"given":"Suresh B.","family":"Boppana","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michiel","family":"van Boven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William J.","family":"Britt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soren","family":"Gantt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul D.","family":"Griffiths","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott D.","family":"Grosse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terri B.","family":"Hyde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatiana M.","family":"Lanzieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marisa M.","family":"Mussi-Pinhata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah E.","family":"Pallas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swetha G.","family":"Pinninti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William D.","family":"Rawlinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shannon A.","family":"Ross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann C.T.M.","family":"Vossen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen B.","family":"Fowler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2023.06.020_b0005","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1002\/path.4437","article-title":"The pathogenesis of human cytomegalovirus","volume":"235","author":"Griffiths","year":"2015","journal-title":"J Pathol"},{"key":"10.1016\/j.vaccine.2023.06.020_b0010","doi-asserted-by":"crossref","DOI":"10.1002\/rmv.2034","article-title":"Estimation of the worldwide seroprevalence of cytomegalovirus: a systematic review and meta-analysis","volume":"29","author":"Zuhair","year":"2019","journal-title":"Rev Med Virol"},{"key":"10.1016\/j.vaccine.2023.06.020_b0015","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1086\/652438","article-title":"Cytomegalovirus seroprevalence in the United States: the national health and nutrition examination surveys, 1988\u20132004","volume":"50","author":"Bate","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2023.06.020_b0020","doi-asserted-by":"crossref","first-page":"e177","DOI":"10.1016\/S1473-3099(17)30143-3","article-title":"Congenital cytomegalovirus infection in pregnancy and the neonate: consensus recommendations for prevention, diagnosis, and therapy","volume":"17","author":"Rawlinson","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2023.06.020_b0025","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1002\/rmv.544","article-title":"New estimates of the prevalence of neurological and sensory sequelae and mortality associated with congenital cytomegalovirus infection","volume":"17","author":"Dollard","year":"2007","journal-title":"Rev Med Virol"},{"key":"10.1016\/j.vaccine.2023.06.020_b0030","doi-asserted-by":"crossref","DOI":"10.1002\/rmv.1938","article-title":"Hearing and neurodevelopmental outcomes for children with asymptomatic congenital cytomegalovirus infection: a systematic review","volume":"27","author":"Bartlett","year":"2017","journal-title":"Rev Med Virol"},{"key":"10.1016\/j.vaccine.2023.06.020_b0035","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1093\/cid\/ciz413","article-title":"Contribution of congenital cytomegalovirus infection to permanent hearing loss in a highly seropositive population: the Brazilian Cytomegalovirus Hearing and Maternal Secondary Infection Study","volume":"70","author":"Yamamoto","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2023.06.020_b0040","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1177\/0194599820921870","article-title":"Etiology of prelingual hearing loss in the universal newborn hearing screening era: a scoping review","volume":"163","author":"Satterfield-Nash","year":"2020","journal-title":"Otolaryngol Neck Surg"},{"key":"10.1016\/j.vaccine.2023.06.020_b0045","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1002\/rmv.655","article-title":"Review of cytomegalovirus seroprevalence and demographic characteristics associated with infection","volume":"20","author":"Cannon","year":"2010","journal-title":"Rev Med Virol"},{"key":"10.1016\/j.vaccine.2023.06.020_b0050","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.20736","article-title":"Congenital cytomegalovirus infection burden and epidemiologic risk factors in countries with universal screening: a systematic review and meta-analysis","volume":"4","author":"Ssentongo","year":"2021","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.vaccine.2023.06.020_b0055","first-page":"172","article-title":"Cytomegalovirus infection in pregnancy: should all women be screened?","volume":"3","author":"Carlson","year":"2010","journal-title":"Rev Obstet Gynecol"},{"key":"10.1016\/j.vaccine.2023.06.020_b0060","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1093\/infdis\/jiy321","article-title":"Seroconversion for cytomegalovirus infection during pregnancy and fetal infection in a highly seropositive population: \u201cThe BraCHS Study\u201d","volume":"218","author":"Mussi-Pinhata","year":"2018","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2023.06.020_b0065","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.jpeds.2018.04.043","article-title":"Racial and ethnic differences in the prevalence of congenital cytomegalovirus infection","volume":"200","author":"Fowler","year":"2018","journal-title":"J Pediatr"},{"key":"10.1016\/j.vaccine.2023.06.020_b0070","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jpids\/piy027","article-title":"The burden of congenital cytomegalovirus infection: a prospective cohort study of 20 000 infants in Finland","volume":"8","author":"Puhakka","year":"2019","journal-title":"J Pediatr Infect Dis Soc"},{"key":"10.1016\/j.vaccine.2023.06.020_b0075","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1002\/jmv.21293","article-title":"Detection of cytomegalovirus, parvovirus B19 and herpes simplex viruses in cases of intrauterine fetal death: association with pathological findings","volume":"80","author":"Syridou","year":"2008","journal-title":"J Med Virol"},{"key":"10.1016\/j.vaccine.2023.06.020_b0080","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1093\/infdis\/jir121","article-title":"Human cytomegalovirus infection is detected frequently in stillbirths and is associated with fetal thrombotic vasculopathy","volume":"203","author":"Iwasenko","year":"2011","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2023.06.020_b0085","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1097\/AOG.0000000000003515","article-title":"Stillbirth associated with infection in a diverse U.S. Cohort","volume":"134","author":"Page","year":"2019","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.vaccine.2023.06.020_b0090","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.jpeds.2013.02.004","article-title":"Viral infections: contributions to late fetal death, stillbirth, and infant death","volume":"163","author":"Williams","year":"2013","journal-title":"J Pediatr"},{"key":"10.1016\/j.vaccine.2023.06.020_b0095","doi-asserted-by":"crossref","unstructured":"Kimberlin DW, Barnett ED, Lynfield R, Sawyer MH, Committee on Infectious Diseases AA of P. Red Book: 2021-2024 Report of the Committee on Infectious Diseases; 2021. Doi: 10.1542\/9781610025782.","DOI":"10.1542\/9781610025225"},{"key":"10.1016\/j.vaccine.2023.06.020_b0100","doi-asserted-by":"crossref","first-page":"133","DOI":"10.7196\/sajch.752","article-title":"Characteristics and mortality rate of neonates with congenital cytomegalovirus infection","volume":"8","author":"Diar","year":"2014","journal-title":"South Afr J Child Health"},{"key":"10.1016\/j.vaccine.2023.06.020_b0105","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0001140","article-title":"Congenital cytomegalovirus mortality in the United States, 1990\u20132006","volume":"5","author":"Bristow","year":"2011","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.vaccine.2023.06.020_b0110","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1111\/jpc.12896","article-title":"Cytomegalovirus-related childhood mortality in A ustralia 1999\u20132011","volume":"51","author":"Smithers-Sheedy","year":"2015","journal-title":"J Paediatr Child Health"},{"key":"10.1016\/j.vaccine.2023.06.020_b0115","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.ejpn.2022.01.019","article-title":"The long-term burden of congenital cytomegalovirus: hospitalisation and mortality in a population-based matched cohort study","volume":"37","author":"Smithers-Sheedy","year":"2022","journal-title":"Eur J Paediatr Neurol EJPN Off J Eur Paediatr Neurol Soc"},{"key":"10.1016\/j.vaccine.2023.06.020_b0120","doi-asserted-by":"crossref","DOI":"10.3390\/microorganisms9081749","article-title":"Congenital human cytomegalovirus infection: a narrative review of maternal immune response and diagnosis in view of the development of a vaccine and prevention of primary and non-primary infections in pregnancy","volume":"9","author":"Gerna","year":"2021","journal-title":"Microorganisms"},{"key":"10.1016\/j.vaccine.2023.06.020_b0125","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1093\/cid\/cix344","article-title":"Public health impact of congenital toxoplasmosis and cytomegalovirus infection in Belgium, 2013: a systematic review and data synthesis","volume":"65","author":"Smit","year":"2017","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2023.06.020_b0130","doi-asserted-by":"crossref","DOI":"10.1097\/INF.0000000000001199","article-title":"Chlamydia trachomatis and Neisseria gonorrhoeae in HIV-infected pregnant women and adverse infant outcomes","volume":"35","author":"Adachi","year":"2016","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2023.06.020_b0135","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.jcv.2005.09.015","article-title":"Congenital cytomegalovirus infection following first trimester maternal infection: symptoms at birth and outcome","volume":"35","author":"Pass","year":"2006","journal-title":"J Clin Virol Off Publ Pan Am Soc Clin Virol"},{"key":"10.1016\/j.vaccine.2023.06.020_b0140","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/j.ajog.2020.05.038","article-title":"Timing of primary maternal cytomegalovirus infection and rates of vertical transmission and fetal consequences","volume":"223","author":"Chatzakis","year":"2020","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.vaccine.2023.06.020_b0145","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1093\/infdis\/jiz443","article-title":"Natural history of congenital cytomegalovirus infection in highly seropositive populations","volume":"221","author":"Mussi-Pinhata","year":"2020","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2023.06.020_b0150","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1002\/rmv.659","article-title":"Cytomegalovirus seroconversion rates and risk factors: implications for congenital CMV","volume":"20","author":"Hyde","year":"2010","journal-title":"Rev Med Virol"},{"key":"10.1016\/j.vaccine.2023.06.020_b0155","doi-asserted-by":"crossref","first-page":"e286","DOI":"10.1542\/peds.2005-1142","article-title":"Risk factors for congenital cytomegalovirus infection in the offspring of young women: exposure to young children and recent onset of sexual activity","volume":"118","author":"Fowler","year":"2006","journal-title":"Pediatrics"},{"key":"10.1016\/j.vaccine.2023.06.020_b0160","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s00430-015-0399-9","article-title":"Controversies in the natural history of congenital human cytomegalovirus infection: the paradox of infection and disease in offspring of women with immunity prior to pregnancy","volume":"204","author":"Britt","year":"2015","journal-title":"Med Microbiol Immunol (Berl)"},{"key":"10.1016\/j.vaccine.2023.06.020_b0165","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1097\/INF.0000000000003072","article-title":"Long-term outcomes after postnatal cytomegalovirus infection in low birthweight preterm infants: a systematic review","volume":"40","author":"Stark","year":"2021","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2023.06.020_b0170","doi-asserted-by":"crossref","first-page":"6393","DOI":"10.1002\/jmv.26815","article-title":"Epidemiology of cytomegalovirus Infection among mothers and infants in Colombia","volume":"93","author":"Rico","year":"2021","journal-title":"J Med Virol"},{"key":"10.1016\/j.vaccine.2023.06.020_b0175","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2020.00661","article-title":"Tuning the orchestra: HCMV vs. innate immunity","volume":"11","author":"Dell\u2019Oste","year":"2020","journal-title":"Front Microbiol"},{"key":"10.1016\/j.vaccine.2023.06.020_b0180","doi-asserted-by":"crossref","DOI":"10.3390\/vaccines7040129","article-title":"Impact of maternal immunity on congenital cytomegalovirus birth prevalence and infant outcomes: a systematic review","volume":"7","author":"Coppola","year":"2019","journal-title":"Vaccines"},{"key":"10.1016\/j.vaccine.2023.06.020_b0185","doi-asserted-by":"crossref","first-page":"3728","DOI":"10.1073\/pnas.1814835116","article-title":"HCMV trimer-and pentamer-specific antibodies synergize for virus neutralization but do not correlate with congenital transmission","volume":"116","author":"Vanarsdall","year":"2019","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.vaccine.2023.06.020_b0190","doi-asserted-by":"crossref","first-page":"E4120","DOI":"10.1073\/pnas.1501880112","article-title":"Limits and patterns of cytomegalovirus genomic diversity in humans","volume":"112","author":"Renzette","year":"2015","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.vaccine.2023.06.020_b0195","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S0022-3476(96)70279-2","article-title":"Cytomegalovirus reinfection in young children","volume":"128","author":"Bale","year":"1996","journal-title":"J Pediatr"},{"key":"10.1016\/j.vaccine.2023.06.020_b0200","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.63199","article-title":"Mixed cytomegalovirus genotypes in HIV-positive mothers show compartmentalization and distinct patterns of transmission to infants","volume":"9","author":"Pang","year":"2020","journal-title":"Elife"},{"issue":"Suppl 3","key":"10.1016\/j.vaccine.2023.06.020_b0205","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/ajt.12006","article-title":"CMV: prevention, Diagnosis and therapy","volume":"13","author":"Kotton","year":"2013","journal-title":"Am J Transplant Off J Am Soc Transplant Am Soc Transpl Surg"},{"key":"10.1016\/j.vaccine.2023.06.020_b0210","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1097\/TP.0000000000002191","article-title":"The third international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation","volume":"102","author":"Kotton","year":"2018","journal-title":"Transplantation"},{"key":"10.1016\/j.vaccine.2023.06.020_b0215","doi-asserted-by":"crossref","first-page":"e1740","DOI":"10.1016\/S2214-109X(21)00407-1","article-title":"Cytomegalovirus acquisition in infancy and the risk of tuberculosis disease in childhood: a longitudinal birth cohort study in Cape Town","volume":"9","author":"Martinez","year":"2021","journal-title":"South Africa Lancet Glob Health"},{"key":"10.1016\/j.vaccine.2023.06.020_b0220","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1136\/archdischild-2017-312805","article-title":"Healthcare costs attributable to congenital cytomegalovirus infection","volume":"103","author":"Korndewal","year":"2018","journal-title":"Arch Dis Child"},{"key":"10.1016\/j.vaccine.2023.06.020_b0225","doi-asserted-by":"crossref","DOI":"10.1016\/j.semperi.2021.151393","article-title":"Economic assessments of the burden of congenital cytomegalovirus infection and the cost-effectiveness of prevention strategies","volume":"45","author":"Grosse","year":"2021","journal-title":"Semin Perinatol"},{"key":"10.1016\/j.vaccine.2023.06.020_b0230","doi-asserted-by":"crossref","first-page":"74","DOI":"10.3201\/eid2301.161322","article-title":"Cost-effectiveness of increasing access to contraception during the Zika Virus Outbreak, Puerto Rico, 2016","volume":"23","author":"Li","year":"2017","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.vaccine.2023.06.020_b0235","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12962-019-0189-0","article-title":"A framework for assessing the lifetime economic burden of congenital cytomegalovirus in the United States","volume":"17","author":"Lucas","year":"2019","journal-title":"Cost Eff Resour Alloc"},{"issue":"Suppl 2","key":"10.1016\/j.vaccine.2023.06.020_b0240","doi-asserted-by":"crossref","first-page":"B197","DOI":"10.1016\/j.vaccine.2012.10.074","article-title":"Desirability and feasibility of a vaccine against cytomegalovirus","volume":"31","author":"Griffiths","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.06.020_b0245","first-page":"39","article-title":"Losing ground: awareness of congenital cytomegalovirus in the United States","volume":"1","author":"Doutre","year":"2016","journal-title":"J Early Hear Detect Interv"},{"key":"10.1016\/j.vaccine.2023.06.020_b0250","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.vaccine.2013.09.042","article-title":"Priorities for CMV vaccine development","volume":"32","author":"Krause","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.06.020_b0255","doi-asserted-by":"crossref","first-page":"S103","DOI":"10.1093\/infdis\/jiz523","article-title":"Scientific and regulatory considerations for efficacy studies of cytomegalovirus vaccines","volume":"221","author":"Krause","year":"2020","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2023.06.020_b0260","doi-asserted-by":"crossref","DOI":"10.1002\/rmv.2011","article-title":"Cytomegalovirus infection in day care centres: a systematic review and meta-analysis of prevalence of infection in children","volume":"29","author":"Zheng","year":"2019","journal-title":"Rev Med Virol"},{"key":"10.1016\/j.vaccine.2023.06.020_b0265","doi-asserted-by":"crossref","first-page":"4713","DOI":"10.1128\/JCM.43.9.4713-4718.2005","article-title":"Diagnosis of and screening for cytomegalovirus infection in pregnant women","volume":"43","author":"Munro","year":"2005","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.vaccine.2023.06.020_b0270","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.jcv.2011.07.005","article-title":"Intrauterine transmission and clinical outcome of 248 pregnancies with primary cytomegalovirus infection in relation to gestational age","volume":"52","author":"Enders","year":"2011","journal-title":"J Clin Virol Off Publ Pan Am Soc Clin Virol"},{"key":"10.1016\/j.vaccine.2023.06.020_b0275","doi-asserted-by":"crossref","DOI":"10.3390\/vaccines9060551","article-title":"Development of a vaccine against human cytomegalovirus: advances, barriers, and implications for the clinical practice","volume":"9","author":"Scarpini","year":"2021","journal-title":"Vaccines"},{"key":"10.1016\/j.vaccine.2023.06.020_b0280","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1007\/s40265-016-0653-5","article-title":"Cytomegalovirus vaccines: current status and future prospects","volume":"76","author":"Anderholm","year":"2016","journal-title":"Drugs"},{"key":"10.1016\/j.vaccine.2023.06.020_b0285","doi-asserted-by":"crossref","first-page":"7437","DOI":"10.1016\/j.vaccine.2018.02.089","article-title":"Vaccination against the human cytomegalovirus","volume":"37","author":"Plotkin","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.06.020_b0290","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1002\/rmv.1790","article-title":"Universal newborn screening for congenital CMV infection: what is the evidence of potential benefit?","volume":"24","author":"Cannon","year":"2014","journal-title":"Rev Med Virol"},{"key":"10.1016\/j.vaccine.2023.06.020_b0295","first-page":"20","article-title":"A review of five years\u2019 experience with rubella vaccine in the United States","volume":"55","author":"Modlin","year":"1975","journal-title":"Pediatrics"},{"key":"10.1016\/j.vaccine.2023.06.020_b0300","doi-asserted-by":"crossref","first-page":"S86","DOI":"10.1093\/infdis\/jiz402","article-title":"Review of mathematical models of vaccination for preventing congenital cytomegalovirus infection","volume":"221","author":"Lanzieri","year":"2020","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2023.06.020_b0305","doi-asserted-by":"crossref","DOI":"10.1186\/s12916-020-01629-3","article-title":"Short- and long-term impact of vaccination against cytomegalovirus: a modeling study","volume":"18","author":"Rozhnova","year":"2020","journal-title":"BMC Med"},{"key":"10.1016\/j.vaccine.2023.06.020_b0310","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1056\/NEJMoa0804749","article-title":"Vaccine prevention of maternal cytomegalovirus infection","volume":"360","author":"Pass","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2023.06.020_b0315","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1002\/jmv.27403","article-title":"Epidemiology of cytomegalovirus infection in pregnancy in Israel: real-world data from a large healthcare organization","volume":"94","author":"Weil","year":"2022","journal-title":"J Med Virol"},{"key":"10.1016\/j.vaccine.2023.06.020_b0320","doi-asserted-by":"crossref","DOI":"10.1186\/s13584-021-00481-x","article-title":"Addressing vaccine hesitancy and access barriers to achieve persistent progress in Israel\u2019s COVID-19 vaccination program","volume":"10","author":"Rosen","year":"2021","journal-title":"Isr J Health Policy Res"},{"key":"10.1016\/j.vaccine.2023.06.020_b0325","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0221725","article-title":"Awareness of congenital cytomegalovirus and acceptance of maternal and newborn screening","volume":"14","author":"Tastad","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2023.06.020_b0330","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.ejogrb.2021.01.035","article-title":"Perspectives of women on screening and prevention of CMV in pregnancy","volume":"258","author":"Beaudoin","year":"2021","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"10.1016\/j.vaccine.2023.06.020_b0335","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1111\/jpc.15705","article-title":"Feasibility and acceptability of targeted salivary cytomegalovirus screening through universal newborn hearing screening","volume":"58","author":"Webb","year":"2022","journal-title":"J Paediatr Child Health"},{"key":"10.1016\/j.vaccine.2023.06.020_b0340","doi-asserted-by":"crossref","DOI":"10.3390\/ijns7040080","article-title":"Family perceptions of newborn cytomegalovirus screening: a qualitative study","volume":"7","author":"Cannon","year":"2021","journal-title":"Int J Neonatal Screen"},{"key":"10.1016\/j.vaccine.2023.06.020_b0345","doi-asserted-by":"crossref","first-page":"3546","DOI":"10.1016\/j.vaccine.2012.03.063","article-title":"Factors associated with HPV vaccine uptake in teenage girls: a systematic review","volume":"30","author":"Kessels","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.06.020_b0350","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0005900","article-title":"A cluster-randomised intervention trial against Schistosoma japonicum in the Peoples\u2019 Republic of China: bovine and human transmission","volume":"4","author":"Gray","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2023.06.020_b0355","doi-asserted-by":"crossref","first-page":"6059","DOI":"10.1016\/j.vaccine.2017.09.046","article-title":"A systematic review of factors affecting vaccine uptake in young children","volume":"35","author":"Smith","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.06.020_b0360","doi-asserted-by":"crossref","DOI":"10.3390\/vaccines10081313","article-title":"COVID-19 pediatric vaccine hesitancy among racially diverse parents in the United States","volume":"10","author":"Fisher","year":"2022","journal-title":"Vaccines"},{"key":"10.1016\/j.vaccine.2023.06.020_b0365","doi-asserted-by":"crossref","unstructured":"Toor J, Li X, Jit M, Trotter CL, Echeverria-Londono S, Hartner A-M, et al. COVID-19 impact on routine immunisations for vaccine-preventable diseases: projecting the effect of different routes to recovery. 2022: 2022.01.07.22268891. Doi: 10.1101\/2022.01.07.22268891.","DOI":"10.1101\/2022.01.07.22268891"},{"key":"10.1016\/j.vaccine.2023.06.020_b0370","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.coi.2021.03.009","article-title":"Supply and delivery of vaccines for global health","volume":"71","author":"Excler","year":"2021","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.vaccine.2023.06.020_b0375","doi-asserted-by":"crossref","first-page":"7208","DOI":"10.1016\/j.vaccine.2021.07.091","article-title":"Strategies for vaccine-product innovation: creating an enabling environment for product development to uptake in low- and middle-income countries","volume":"39","author":"Giersing","year":"2021","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.06.020_b0380","unstructured":"Institute of Medicine (US) Committee to Study Priorities for Vaccine Development. Vaccines for the 21st Century: a Tool for Decisionmaking. Washington (DC): National Academies Press (US); 2000."},{"key":"10.1016\/j.vaccine.2023.06.020_b0385","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1086\/421999","article-title":"Vaccine development to prevent cytomegalovirus disease: report from the national vaccine advisory committee","volume":"39","author":"Modlin","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2023.06.020_b0390","unstructured":"Public Health Agency of Canada. Vaccine research and development priorities; 2014. https:\/\/www.canada.ca\/en\/public-health\/services\/vaccine-research-development-priorities.html [accessed August 13, 2022]."},{"key":"10.1016\/j.vaccine.2023.06.020_b0395","unstructured":"National CMV Foundation. CMV Vaccines and Clinical Trials | National CMV Foundation | National CMV Foundation n.d. https:\/\/www.nationalcmv.org\/overview\/vaccine-development [accessed August 13, 2022]."},{"key":"10.1016\/j.vaccine.2023.06.020_b0400","unstructured":"National CMV Foundation. National CMV Foundation - Cytomegalovirus (CMV) | National CMV Foundation; n.d. https:\/\/www.nationalcmv.org\/ [accessed August 13, 2022]."},{"key":"10.1016\/j.vaccine.2023.06.020_b0405","unstructured":"CMV Canada. Homepage. CMV Can - Lets Talk CMV; n.d. https:\/\/cmvcanada.com\/ [accessed August 13, 2022]."},{"key":"10.1016\/j.vaccine.2023.06.020_b0410","unstructured":"CMV action, UK. CMV Action - What is CMV? CMV Action; n.d. https:\/\/cmvaction.org.uk\/ [accessed August 13, 2022]."},{"key":"10.1016\/j.vaccine.2023.06.020_b0415","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1136\/archdischild-2018-316010","article-title":"Economic cost of congenital CMV in the UK","volume":"104","author":"Retzler","year":"2019","journal-title":"Arch Dis Child"},{"key":"10.1016\/j.vaccine.2023.06.020_b0420","unstructured":"StopCMV. Citomegalovirus Chile. StopCMV; n.d. https:\/\/www.stopcmv.cl [accessed August 13, 2022]."},{"key":"10.1016\/j.vaccine.2023.06.020_b0425","unstructured":"FamiliasCMV. Asociaci\u00f3n Familias CMV - Asociaci\u00f3n de Familias con Citomegalovirus Cong\u00e9nito; n.d. https:\/\/familiascmv.org\/ [accessed August 13, 2022]."},{"key":"10.1016\/j.vaccine.2023.06.020_b0430","unstructured":"Spolu proti CMV. Spolu proti CMV. spoluproticmv.sk; n.d. http:\/\/www.spoluproticmv.sk\/ [accessed August 13, 2022]."},{"key":"10.1016\/j.vaccine.2023.06.020_b0435","unstructured":"associationCMV. CMV - Just another WordPress site; n.d. https:\/\/stopcmv.fr\/ [accessed August 15, 2022]."},{"key":"10.1016\/j.vaccine.2023.06.020_b0440","unstructured":"Torch Association. Torch Association - Congenital Toxoplasma & Cytomegalovirus Patient Association | n.d. https:\/\/toxo-cmv.org\/ [accessed August 13, 2022]."},{"key":"10.1016\/j.vaccine.2023.06.020_b0445","unstructured":"The Israeli association for pregnancy with CMV. \u05d4\u05e2\u05de\u05d5\u05d3 \u05dc\u05d0 \u05e0\u05de\u05e6\u05d0. \u05d4\u05e2\u05de\u05d5\u05ea\u05d4 \u05d4\u05d9\u05e9\u05e8\u05d0\u05dc\u05d9\u05ea \u05dc\u05d4\u05d9\u05e8\u05d9\u05d5\u05df \u05e2\u05dd CMV; n.d. https:\/\/www.cmv.co.il\/cmv-homepage-english [accessed August 13, 2022]."},{"key":"10.1016\/j.vaccine.2023.06.020_b0450","unstructured":"AntiCito Onlus. CMV adovocay; n.d. http:\/\/www.anticito.org\/."},{"key":"10.1016\/j.vaccine.2023.06.020_b0455","unstructured":"CMV Australia. CCMV Home. CCMV; n.d. https:\/\/www.cmv.org.au\/ [accessed August 13, 2022]."},{"key":"10.1016\/j.vaccine.2023.06.020_b0460","unstructured":"MCA. ECCI 2020 - European Congenital Cytomegalovirus Initiative; n.d. https:\/\/www.mcascientificevents.eu\/ecci\/ [accessed August 13, 2022]."},{"key":"10.1016\/j.vaccine.2023.06.020_b0465","unstructured":"CMV 2022. 8th International Congenital CMV Conference & 18th International CMV Workshop - 28 March - 1 April 2022, Virtual; n.d. https:\/\/www.cmv2022.org\/ [accessed August 13, 2022]."},{"key":"10.1016\/j.vaccine.2023.06.020_b0470","unstructured":"CMV Conference; n.d. https:\/\/cmv.usu.edu\/ [accessed August 13, 2022]."},{"key":"10.1016\/j.vaccine.2023.06.020_b0475","unstructured":"International Herpesvirus Workshop; n.d. https:\/\/www.herpesvirusworkshop.com\/ [accessed August 13, 2022]."},{"key":"10.1016\/j.vaccine.2023.06.020_b0480","unstructured":"HRSA. Maternal and Child Health Bureau | MCHB; n.d. https:\/\/mchb.hrsa.gov\/ [accessed August 14, 2022]."},{"key":"10.1016\/j.vaccine.2023.06.020_b0485","unstructured":"HRSA. Official web site of the U.S. Health Resources & Services Administration. Off Web Site US Health Resour Serv Adm; n.d. https:\/\/www.hrsa.gov\/ [accessed August 14, 2022]."},{"key":"10.1016\/j.vaccine.2023.06.020_b0490","unstructured":"NCHAM. Newborn Hearing Screening and Early Hearing Detection & Intervention Resources | NCHAM; n.d. https:\/\/www.infanthearing.org\/index.html [accessed August 13, 2022]."},{"key":"10.1016\/j.vaccine.2023.06.020_b0495","unstructured":"Baylor College of Medicine. Congenital CMV Disease Research Clinic & Registry. Bayl Coll Med; n.d. https:\/\/www.bcm.edu\/departments\/pediatrics\/divisions-and-centers\/congenital-cmv-disease-research-clinic-registry [accessed August 13, 2022]."},{"key":"10.1016\/j.vaccine.2023.06.020_b0500","unstructured":"CDC. Cytomegalovirus (CMV) and Congenital CMV Infection | CDC 2021. https:\/\/www.cdc.gov\/cmv\/index.html [accessed August 14, 2022]."},{"key":"10.1016\/j.vaccine.2023.06.020_b0505","unstructured":"CDC. CMV Resource Center | CDC; 2022. https:\/\/www.cdc.gov\/cmv\/resources\/index.html [accessed August 14, 2022]."},{"key":"10.1016\/j.vaccine.2023.06.020_b0510","unstructured":"CDC. National Cytomegalovirus (CMV) Awareness Month | CDC; 2021. https:\/\/www.cdc.gov\/cmv\/awareness-month.html [accessed August 14, 2022]."},{"key":"10.1016\/j.vaccine.2023.06.020_b0515","unstructured":"CDC. About Cytomegalovirus and Congenital CMV Infection | CDC; 2022. https:\/\/www.cdc.gov\/cmv\/overview.html [accessed August 13, 2022]."},{"key":"10.1016\/j.vaccine.2023.06.020_b0520","unstructured":"National CMV Foundation. CMV Legislation | National CMV Foundation | National CMV Foundation; n.d. https:\/\/www.nationalcmv.org\/about-us\/advocacy [accessed August 13, 2022]."},{"key":"10.1016\/j.vaccine.2023.06.020_b0525","unstructured":"NSO Canada. Overview | CHEO NSO; n.d. https:\/\/www.newbornscreening.on.ca\/en\/page\/overview [accessed August 13, 2022]."},{"key":"10.1016\/j.vaccine.2023.06.020_b0530","unstructured":"World Health Organization. Preferred Product Characteristics and Target Product Profiles; n.d. https:\/\/www.who.int\/teams\/immunization-vaccines-and-biologicals\/product-and-delivery-research\/ppcs [accessed August 15, 2022]."},{"key":"10.1016\/j.vaccine.2023.06.020_b0535","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/S0140-6736(88)90685-X","article-title":"Symptomatic cytomegalovirus infection in seropositive kidney recipients: reinfection with donor virus rather than reactivation of recipient virus","volume":"2","author":"Grundy","year":"1988","journal-title":"Lancet Lond Engl"},{"key":"10.1016\/j.vaccine.2023.06.020_b0540","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1111\/j.1600-6143.2012.04087.x","article-title":"Cytomegalovirus replication kinetics in solid organ transplant recipients managed by preemptive therapy","volume":"12","author":"Atabani","year":"2012","journal-title":"Am J Transplant Off J Am Soc Transplant Am Soc Transpl Surg"},{"key":"10.1016\/j.vaccine.2023.06.020_b0545","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1093\/cid\/cix793","article-title":"Use of viral load as a surrogate marker in clinical studies of cytomegalovirus in solid organ transplantation: a systematic review and meta-analysis","volume":"66","author":"Natori","year":"2018","journal-title":"Clin Infect Dis Off Publ Infect Dis Soc Am"},{"key":"10.1016\/j.vaccine.2023.06.020_b0550","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1016\/S0140-6736(11)60136-0","article-title":"Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trial","volume":"377","author":"Griffiths","year":"2011","journal-title":"Lancet Lond Engl"},{"key":"10.1016\/j.vaccine.2023.06.020_b0555","doi-asserted-by":"crossref","first-page":"6273","DOI":"10.1073\/pnas.1800224115","article-title":"Protection from cytomegalovirus viremia following glycoprotein B vaccination is not dependent on neutralizing antibodies","volume":"115","author":"Baraniak","year":"2018","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.vaccine.2023.06.020_b0560","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.ebiom.2019.11.005","article-title":"Seronegative patients vaccinated with cytomegalovirus gB-MF59 vaccine have evidence of neutralising antibody responses against gB early post-transplantation","volume":"50","author":"Baraniak","year":"2019","journal-title":"EBioMedicine"},{"key":"10.1016\/j.vaccine.2023.06.020_b0585","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1016\/S0264-410X(00)00377-7","article-title":"Encouraging prospects for immunisation against primary cytomegalovirus infection","volume":"19","author":"Griffiths","year":"2001","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.06.020_b0590","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.vaccine.2015.11.056","article-title":"Safety and efficacy of a cytomegalovirus glycoprotein B (gB) vaccine in adolescent girls: a randomized clinical trial","volume":"34","author":"Bernstein","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.06.020_b0595","doi-asserted-by":"crossref","first-page":"6267","DOI":"10.1073\/pnas.1800177115","article-title":"HCMV glycoprotein B subunit vaccine efficacy mediated by nonneutralizing antibody effector functions","volume":"115","author":"Nelson","year":"2018","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.vaccine.2023.06.020_b0600","doi-asserted-by":"crossref","first-page":"e01695","DOI":"10.1128\/JVI.01695-18","article-title":"Intrahost dynamics of human cytomegalovirus variants acquired by seronegative glycoprotein B vaccinees","volume":"93","author":"Nelson","year":"2019","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2023.06.020_b0605","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abb3611","article-title":"Antibody binding to native cytomegalovirus glycoprotein B predicts efficacy of the gB\/MF59 vaccine in humans","volume":"12","author":"Jenks","year":"2020","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.vaccine.2023.06.020_b0610","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1056\/NEJMoa1006561","article-title":"Saliva polymerase-chain-reaction assay for cytomegalovirus screening in newborns","volume":"364","author":"Boppana","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2023.06.020_b0615","doi-asserted-by":"crossref","first-page":"e205441","DOI":"10.1001\/jamapediatrics.2020.5441","article-title":"Sensitivity of dried blood spot testing for detection of congenital cytomegalovirus infection","volume":"175","author":"Dollard","year":"2021","journal-title":"JAMA Pediatr"},{"key":"10.1016\/j.vaccine.2023.06.020_b0620","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1001\/jama.2010.423","article-title":"Dried blood spot real-time polymerase chain reaction assays to screen newborns for congenital cytomegalovirus infection","volume":"303","author":"Boppana","year":"2010","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2023.06.020_b0625","doi-asserted-by":"crossref","first-page":"S45","DOI":"10.1093\/infdis\/jiz428","article-title":"Immune correlates of protection against human cytomegalovirus acquisition, replication, and disease","volume":"221","author":"Nelson","year":"2020","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2023.06.020_b0630","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1056\/NEJM198204223061601","article-title":"Congenital cytomegalovirus infection: the relative importance of primary and recurrent maternal infection","volume":"306","author":"Stagno","year":"1982","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2023.06.020_b0635","doi-asserted-by":"crossref","unstructured":"Mussi-Pinhata MM, Yamamoto AY, Moura Brito RM, de Lima Isaac M, de Carvalho e Oliveira PF, Boppana S, et al. Birth prevalence and natural history of congenital cytomegalovirus infection in a highly seroimmune population. Clin Infect Dis Off Publ Infect Dis Soc Am 2009; 49: 522\u20138. Doi: 10.1086\/600882.","DOI":"10.1086\/600882"},{"key":"10.1016\/j.vaccine.2023.06.020_b0640","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1093\/cid\/cit018","article-title":"Long-term outcomes of congenital cytomegalovirus infection in Sweden and the United Kingdom","volume":"56","author":"Townsend","year":"2013","journal-title":"Clin Infect Dis Off Publ Infect Dis Soc Am"},{"key":"10.1016\/j.vaccine.2023.06.020_b0645","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1002\/rmv.535","article-title":"Review and meta-analysis of the epidemiology of congenital cytomegalovirus (CMV) infection","volume":"17","author":"Kenneson","year":"2007","journal-title":"Rev Med Virol"},{"key":"10.1016\/j.vaccine.2023.06.020_b0650","doi-asserted-by":"crossref","first-page":"e11","DOI":"10.1093\/cid\/ciq085","article-title":"Attribution of congenital cytomegalovirus infection to primary versus non-primary maternal infection","volume":"52","author":"Wang","year":"2011","journal-title":"Clin Infect Dis Off Publ Infect Dis Soc Am"},{"key":"10.1016\/j.vaccine.2023.06.020_b0655","doi-asserted-by":"crossref","first-page":"e02392","DOI":"10.1128\/JVI.02392-16","article-title":"Congenital human cytomegalovirus infection and the enigma of maternal immunity","volume":"91","author":"Britt","year":"2017","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2023.06.020_b0660","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1093\/cid\/cix621","article-title":"Universal screening with use of immunoglobulin G avidity for congenital cytomegalovirus infection","volume":"65","author":"Tanimura","year":"2017","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2023.06.020_b0665","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1093\/cid\/cix337","article-title":"Risk factors for congenital cytomegalovirus infection following primary and nonprimary maternal infection: A prospective neonatal screening study using polymerase chain reaction in Saliva","volume":"65","author":"Leruez-Ville","year":"2017","journal-title":"Clin Infect Dis Off Publ Infect Dis Soc Am"},{"key":"10.1016\/j.vaccine.2023.06.020_b0670","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcv.2020.104518","article-title":"Maternal type of CMV infection and sequelae in infants with congenital CMV: systematic review and meta-analysis","volume":"129","author":"Maltezou","year":"2020","journal-title":"J Clin Virol Off Publ Pan Am Soc Clin Virol"},{"key":"10.1016\/j.vaccine.2023.06.020_b0675","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1080\/22221751.2021.1969290","article-title":"Maternal CMV seroprevalence rate in early gestation and congenital cytomegalovirus infection in a Chinese population","volume":"10","author":"Huang","year":"2021","journal-title":"Emerg Microbes Infect"},{"key":"10.1016\/j.vaccine.2023.06.020_b0680","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1086\/382533","article-title":"Interval between births and risk of congenital cytomegalovirus infection","volume":"38","author":"Fowler","year":"2004","journal-title":"Clin Infect Dis Off Publ Infect Dis Soc Am"},{"key":"10.1016\/j.vaccine.2023.06.020_b0695","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1056\/NEJMoa1913569","article-title":"A trial of hyperimmune globulin to prevent congenital cytomegalovirus infection","volume":"385","author":"Hughes","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2023.06.020_b0700","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1056\/NEJMoa1310214","article-title":"A randomized trial of hyperimmune globulin to prevent congenital cytomegalovirus","volume":"370","author":"Revello","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2023.06.020_b0705","unstructured":"ModernaTX, Inc. A Phase 1, Randomized, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety and Immunogenicity of VAL-181388 in Healthy Adults in a Non Endemic Chikungunya Region. clinicaltrials.gov; 2020."},{"key":"10.1016\/j.vaccine.2023.06.020_b0710","unstructured":"Merck Sharp & Dohme LLC. A Phase 1 Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Immunogenicity of the Human Cytomegalovirus Vaccine (V160) in Healthy Adults. clinicaltrials.gov; 2021."},{"key":"10.1016\/j.vaccine.2023.06.020_b0715","unstructured":"Merck Sharp & Dohme LLC. Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 (Cytomegalovirus [CMV] Vaccine) in Healthy Seronegative Women, 16 to 35 Years of Age. clinicaltrials.gov; 2021."},{"key":"10.1016\/j.vaccine.2023.06.020_b0720","unstructured":"GlaxoSmithKline. A Phase 1\/2, First-Time-in Human (FTiH), Randomized, Observer-blind, Placebo-controlled, Dose Escalation Study to Assess Safety, Reactogenicity and Immunogenicity of a Candidate Cytomegalovirus (CMV) Vaccine Comprising Recombinant Protein and Adjuvant When Administered Intramuscularly in Healthy Adults. clinicaltrials.gov; 2022."},{"key":"10.1016\/j.vaccine.2023.06.020_b0725","unstructured":"VBI Vaccines Inc. A Phase 1 Randomized, Observer-Blind, Placebo-Controlled, Study to Evaluate the Safety, Tolerability, and Immunogenicity of the Candidate Human Cytomegalovirus Vaccine (VBI-1501) in Healthy Adults. clinicaltrials.gov; 2020."},{"key":"10.1016\/j.vaccine.2023.06.020_b0730","unstructured":"National Institute of Allergy and Infectious Diseases (NIAID). A Randomized, Double-Blind, Placebo-Controlled, Phase II Study to Assess the Safety and Efficacy of the Cytomegalovirus gB\/MF59 Vaccine in Preventing Systemic Cytomegalovirus Infection in Healthy Adolescent Females. clinicaltrials.gov; 2017."},{"key":"10.1016\/j.vaccine.2023.06.020_b0735","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1017\/S0950268811000343","article-title":"Modelling immunization strategies with cytomegalovirus vaccine candidates","volume":"139","author":"Azevedo","year":"2011","journal-title":"Epidemiol Infect"},{"key":"10.1016\/j.vaccine.2023.06.020_b0740","doi-asserted-by":"crossref","first-page":"3780","DOI":"10.1016\/j.vaccine.2014.05.014","article-title":"Modeling the potential impact of vaccination on the epidemiology of congenital cytomegalovirus infection","volume":"32","author":"Lanzieri","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.06.020_b0745","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1080\/21645515.2015.1016665","article-title":"A dynamic transmission model with age-dependent infectiousness and reactivation for cytomegalovirus in the United States: potential impact of vaccination strategies on congenital infection","volume":"11","author":"Hogea","year":"2015","journal-title":"Hum Vaccines Immunother"},{"key":"10.1016\/j.vaccine.2023.06.020_b0750","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.vaccine.2015.11.039","article-title":"Optimizing age of cytomegalovirus screening and vaccination to avert congenital disease in the US","volume":"34","author":"Alfaro-Murillo","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.06.020_b0755","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1111\/dmcn.13556","article-title":"Long-term impairment attributable to congenital cytomegalovirus infection: a retrospective cohort study","volume":"59","author":"Korndewal","year":"2017","journal-title":"Dev Med Child Neurol"},{"key":"10.1016\/j.vaccine.2023.06.020_b0760","doi-asserted-by":"crossref","first-page":"5179","DOI":"10.1016\/j.vaccine.2022.07.026","article-title":"Modestly protective cytomegalovirus vaccination of young children effectively prevents congenital infection at the population level","volume":"40","author":"Byrne","year":"2022","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.06.020_b0765","doi-asserted-by":"crossref","first-page":"3675","DOI":"10.1128\/JVI.79.6.3675-3683.2005","article-title":"Long-term cytomegalovirus infection leads to significant changes in the composition of the CD8+ T-cell repertoire, which may be the basis for an imbalance in the cytokine production profile in elderly persons","volume":"79","author":"Almanzar","year":"2005","journal-title":"J Virol"},{"issue":"169","key":"10.1016\/j.vaccine.2023.06.020_b0770","first-page":"1984","article-title":"Cytomegalovirus seropositivity drives the CD8 T cell repertoire toward greater clonality in healthy elderly individuals","volume":"2002","author":"Khan","year":"1950","journal-title":"J Immunol Baltim Md"},{"key":"10.1016\/j.vaccine.2023.06.020_b0775","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1038\/nri.2016.38","article-title":"T cell responses to cytomegalovirus","volume":"16","author":"Klenerman","year":"2016","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.vaccine.2023.06.020_b0780","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.exger.2013.11.010","article-title":"Immunosenenescence: role of cytomegalovirus","volume":"54","author":"Pawelec","year":"2014","journal-title":"Exp Gerontol"},{"key":"10.1016\/j.vaccine.2023.06.020_b0785","doi-asserted-by":"crossref","first-page":"4060","DOI":"10.1016\/j.vaccine.2012.04.011","article-title":"Cost-effectiveness of routine vaccination of adolescent females against cytomegalovirus","volume":"30","author":"Dempsey","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.06.020_b0790","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1016\/j.vaccine.2018.01.042","article-title":"Cost-effectiveness of vaccination against cytomegalovirus (CMV) in adolescent girls to prevent infections in pregnant women living in France","volume":"36","author":"N\u2019Diaye","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.06.020_b0795","series-title":"Congenit. Cytomegalovirus Infect. Epidemiol. Diagn. Ther.","first-page":"121","article-title":"How to save money: congenital CMV infection and the economy","author":"Walter","year":"2011"},{"issue":"126","key":"10.1016\/j.vaccine.2023.06.020_b0800","first-page":"849","article-title":"Impact of vision loss on costs and outcomes in medicare beneficiaries with glaucoma","volume":"2008","author":"Bramley","year":"1960","journal-title":"Arch Ophthalmol Chic Ill"},{"key":"10.1016\/j.vaccine.2023.06.020_b0805","unstructured":"World Health Organization. Guidance for the development of evidence-based vaccine-related recommendations n.d. https:\/\/www.who.int\/publications\/m\/item\/guidance-for-the-development-of-evidence-based-vaccine-related-recommendations [accessed August 14, 2022]."},{"key":"10.1016\/j.vaccine.2023.06.020_b0810","unstructured":"Gavi. Vaccine investment strategy n.d. https:\/\/www.gavi.org\/our-alliance\/strategy\/vaccine-investment-strategy [accessed August 14, 2022]."},{"key":"10.1016\/j.vaccine.2023.06.020_b0815","series-title":"Principles and considerations for adding a vaccine to a national immunization programme: from decision to implementation and monitoring","author":"World Health Organization","year":"2014"},{"key":"10.1016\/j.vaccine.2023.06.020_b0820","unstructured":"Moderna TX, Inc. A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age. clinicaltrials.gov; 2022."},{"key":"10.1016\/j.vaccine.2023.06.020_b0825","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1111\/ajo.12978","article-title":"Knowledge of congenital cytomegalovirus (CMV) in pregnant women in Australia is low, and improved with education","volume":"59","author":"Lazzaro","year":"2019","journal-title":"Aust N Z J Obstet Gynaecol"},{"key":"10.1016\/j.vaccine.2023.06.020_b0830","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1515\/jpm-2020-0301","article-title":"Pregnant women\u2019s knowledge and behaviour to prevent cytomegalovirus infection: an observational study","volume":"49","author":"Vena","year":"2021","journal-title":"J Perinat Med"},{"key":"10.1016\/j.vaccine.2023.06.020_b0835","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcv.2020.104335","article-title":"Evolution of awareness and knowledge of congenital cytomegalovirus infection among health care providers in France between 2011 and 2018","volume":"129","author":"Fellah","year":"2020","journal-title":"J Clin Virol Off Publ Pan Am Soc Clin Virol"},{"key":"10.1016\/j.vaccine.2023.06.020_b0840","doi-asserted-by":"crossref","first-page":"8875494","DOI":"10.1155\/2020\/8875494","article-title":"Improving obstetric provider congenital cytomegalovirus knowledge and practices","volume":"2020","author":"Pesch","year":"2020","journal-title":"Infect Dis Obstet Gynecol"},{"key":"10.1016\/j.vaccine.2023.06.020_b0845","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1186\/s12199-021-01029-w","article-title":"Awareness and knowledge of congenital cytomegalovirus infection among pregnant women and the general public: a web-based survey in Japan","volume":"26","author":"Kobayashi","year":"2021","journal-title":"Environ Health Prev Med"},{"key":"10.1016\/j.vaccine.2023.06.020_b0850","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1016\/j.ebiom.2015.08.003","article-title":"Prevention of primary cytomegalovirus infection in pregnancy","volume":"2","author":"Revello","year":"2015","journal-title":"EBioMedicine"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X23006709?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X23006709?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:31:23Z","timestamp":1759404683000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X23006709"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":164,"alternative-id":["S0264410X23006709"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2023.06.020","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Vaccine value profile for cytomegalovirus","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2023.06.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}